Search results for "Haemophilia A"

showing 10 items of 28 documents

Acquired haemophilia A: a case repor

2009

Acquired haemophilia A
researchProduct

Secondary prophylaxis vs. on-demand treatment to improve quality of life in severe adult haemophilia A patients: a prospective study in a single cent…

2013

Background Retrospective publications show a decrease in the bleeding frequency and an improvement in the quality of life (QoL) in severe adult haemophilia A (SAHA) after switching from the on-demand treatment (DT) to secondary prophylaxis (SP). But there are no prospective studies which demonstrate, using a haemophilia-specific questionnaire, an improvement in the QoL after such treatment change. The main objective of this study is to prospectively compare the QoL and the musculoskeletal assessment after switching from DT to SP in SAHA using the A36 Hemofilia-QoL®. As secondary objective, we compare the haemarthrosis frequency and factor VIII consumption in DT and SP during a similar perio…

AdultMalePediatricsmedicine.medical_specialtyHaemophilia Ahaemophilia AHemorrhageHemophilia AQuality of lifeSurveys and QuestionnairesHemarthrosismedicineHumansProspective StudiesProspective cohort studyRetrospective StudiesmusculoskeletalFactor VIIIbusiness.industrySecondary prophylaxisHematologyGeneral MedicineMiddle Agedmedicine.diseasehumanitiesbleeding incidenceSingle centreOn demand treatmentquality of lifesecondary prophylaxisQuality of LifeFemalebusinessVox sanguinis
researchProduct

Predictive factors of immune tolerance treatment response in severe haemophilia A patients with inhibitors: A real‐world report from a single centre,…

2019

AdultMalePediatricsmedicine.medical_specialtyTreatment responseOnline LettersMEDLINEHemophilia AImmune toleranceHumansMedicineProspective StudiesTreatment FailureChildLetters to the EditorProspective cohort studyLetter to the EditorGenetics (clinical)Retrospective StudiesFactor VIIIbusiness.industryRetrospective cohort studyHematologyGeneral MedicineSingle centreLong term learningFemaleSevere haemophilia AbusinessHaemophilia
researchProduct

Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A

2018

Introduction: Personalised pharmacokinetics (PK) using Bayesian analysis with limited sampling is assumed to help to optimise prophylaxis in haemophilia A (HA) patients. Materials and methods: Our prospective, observational study analysed the influence of PK parameters on clinical variables (bleeding rates, joint status, adherence, and consumption) using myPKFiT (R) in a cohort of twenty-one severe and moderate HA patients on prophylaxis with recombinant FVIII (Advate (R)) in two periods of one year, the first before PK-based tailoring and the second after PK-guided prophylaxis. Intra-individual and inter-individual coefficients of variation (CV) of half-life (t(1/2)) were calculated. Resul…

AdultMalemedicine.medical_specialtyAdolescentHaemophilia AModerate haemophilia A030204 cardiovascular system & hematologyHemophilia ARecombinant factor viiiRecombinant factor VIIIYoung Adult03 medical and health sciences0302 clinical medicinePharmacokineticsInternal medicineHaemophilia AArthropathymedicineLimited samplingHumansPharmacokineticsProspective StudiesAgedFactor VIIIbusiness.industryBayes TheoremHematologyBayesian estimationMiddle Agedmedicine.diseasePK-guided prophylaxis030220 oncology & carcinogenesisCohortFemaleObservational studybusinessmyPKFiTThrombosis Research
researchProduct

Surface electrical stimulation of the quadriceps femoris in patients affected by haemophilia A.

2006

Eighteen sessions of surface electrical stimulation was applied to the quadriceps femoris of the left leg of ten male subjects affected by severe haemophilia A, while ten healthy subjects constituted the control group. The isometric strength, the electromyographic activity and the diameter of the rectus femoris were measured in both legs before and after a six-week treatment period. After the treatment, the people affected by haemophilia showed a gain in strength by 13.8% in the stimulated leg and by 17.1% in the non-stimulated one. No changes were detected in the electromyographic activity. On the contrary, the diameter of the rectus femoris of the stimulated leg increased in 24.34%, while…

AdultMalemedicine.medical_specialtyAdolescentHaemophilia AStimulationElectric Stimulation TherapyIsometric exerciseHaemophiliaHemophilia AQuadriceps MusclePhysical medicine and rehabilitationIsometric ContractionmedicineHumansIn patientGenetics (clinical)business.industryHealthy subjectsHematologyGeneral MedicineMiddle Agedmedicine.diseaseTreatment periodAnesthesiaCase-Control StudiesSevere haemophilia AbusinessHaemophilia : the official journal of the World Federation of Hemophilia
researchProduct

Tailoring haemophilia A prophylaxis with BAY 81-8973: A case series

2020

BAY 81-8973 is an unmodified, full-length third generation recombinant factor VIII (rFVIII) which offers a more favorable pharmacokinetic (PK) profile, compared to its predecessor sucrose-formulated rFVIII (rFVIII-FS). We here report on a retrospective case series of nine patients affected by hemophilia A (HA), with variable disease severity, bleeding phenotype and comorbidities, to underline our clinical practice on prophylaxis with a recently introduced standard hall-life recombinant Factor VIII. The current case series highlights how the current clinical management of hemophilia is able to personalize treatment in several specific conditions like concomitant illnesses with thrombotic ris…

AdultMalemedicine.medical_specialtyAdolescentHemophilia A HemarthrosisHemophilic arthropathyrFVIIIPharmacokineticProphylaxisHaemophilia A030204 cardiovascular system & hematologyHemophilia ARecombinant factor viii03 medical and health sciencesYoung Adult0302 clinical medicinehemic and lymphatic diseasesInternal medicineMedicineHumansChildVariable disease severityAgedRetrospective StudiesThrombotic riskFactor VIIIbusiness.industryHematologyHemarthrosisMiddle Agedmedicine.diseaseThird generationClinical PracticeTreatment OutcomeConcomitantbusiness030215 immunology
researchProduct

Management of dental extraction in patients with Haemophilia A and B: a report of 58 extractions

2013

Objectives: Patients with inherited bleeding disorders are at high risk of bleeding following oral surgery and present challenges to the oral surgeons. Aim of this study was to report our experience in dental extraction in patients exhibiting Haemophilia A and B between 2007 and 2012. Patient and Methods: 58 dental extractions in 15 patients during 19 interventions were performed. Replacement therapy with recombinant and plasma-derived factor VIII and IX was applied systematically in combination with antifibrinolytic treatment and local haemostatic measures. The following data were recorded: type of surgery, applied local haemostatic measures, general substitution, systemic antifibrinolytic…

AdultMalemedicine.medical_specialtyAntifibrinolyticAdolescentOral Surgeonmedicine.drug_classmedicine.medical_treatmentHaemophilia AOdontologíaPostoperative HemorrhageHaemophiliaHemophilia AHemophilia BHemostaticsYoung AdultAntifibrinolytic agentmedicineHumansChildGeneral DentistryAgedbusiness.industryHemostatic TechniquesResearchMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludSurgeryHemostaticsOtorhinolaryngologyDental extractionChild PreschoolTooth ExtractionUNESCO::CIENCIAS MÉDICASSurgeryFemaleTamponadeOral Surgerybusiness
researchProduct

Immune tolerance induction with moroctocog-alpha (Refacto/Refacto AF) in a population of Italian haemophilia A patients with high-titre inhibitors: D…

2019

Background: The appearance of inhibitors is the most serious complication in haemophilia A (HA) patients. The primary objective is their eradication. Up to date, immune tolerance induction (ITI) was the only therapeutic option to achieve this. Aim: To assess the efficacy of moroctocog-alpha as an ITI regimen in a population of HA patients with high-titre inhibitors. Methods: The REF.IT Registry is a retrospective-prospective study that collected data on all patients with HA and high-titre inhibitors treated with moroctocog-alpha as an ITI regimen at twelve Italian Haemophilia Centres. Results: We enrolled 27 patients, 85.2% were children. All patients were high responders, 88.9% had severe …

AdultMalemedicine.medical_specialtyPopulationHaemophilia AAlpha (ethology)030204 cardiovascular system & hematologyHaemophiliaHemophilia Ahaemophilia A with inhibitors; immune tolerance induction; moroctocog-alpha; poor-prognosis ITI patients; Adult; Child; Child Preschool; Factor VIII; Female; Hemophilia A; Humans; Immune Tolerance; Italy; Male; Prospective Studies; Retrospective Studies; Risk Factors; RegistriesImmune tolerance03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineImmune ToleranceMedicineHumansProspective StudiesRegistrieseducationHigh titrePreschoolChildGenetics (clinical)Retrospective Studiesimmune tolerance inductioneducation.field_of_studyFactor VIIIbusiness.industryHematologyGeneral Medicinehaemophilia A with inhibitormedicine.diseasepoor-prognosis ITI patientsRegimenItalymoroctocog-alphaChild PreschoolFemalebusinessComplicationhaemophilia A with inhibitors030215 immunologyHaemophilia : the official journal of the World Federation of HemophiliaREFERENCES
researchProduct

Results of an orthopaedic survey in young patients with severe haemophilia in Spain

2002

Summary.  This paper outlines the results obtained in a cross-sectional study of a group of young patients with severe haemophilia A and B. The primary aim of the study was to ascertain the level of orthopaedic complications in the group, the effects that these complications have on quality of life, and the medical resources used on these patients. The secondary aim was to relate their current orthopaedic state to the type of treatment received before the study. The study was carried out in 11 hospitals in Spain, where 70 severe haemophilia patients (factor VIII [FVIII] < 2%), with an average age of 21.6 and a median age of 22, and no inhibitors, were monitored. The percentage of patients s…

AdultPediatricsmedicine.medical_specialtyAdolescentHaemophilia AHemophilia AHaemophiliaHemophilia BCost of IllnessQuality of lifeOn demandAbsenteeismHemarthrosismedicineHumansYoung adultGenetics (clinical)Retrospective StudiesHaemophilic arthropathybusiness.industrySecondary prophylaxisHematologyGeneral Medicinemedicine.diseaseArthralgiaCross-Sectional StudiesSpainQuality of LifeSevere haemophilia AbusinessHaemophilia
researchProduct

Influence of aquatic training on the motor performance of patients with haemophilic arthropathy

2009

Thirteen patients with haemophilia A took part in this study voluntarily. They underwent an aquatic training programme over a 9-week period (27 sessions; three sessions per week; 1 h per session). Their motor performance was assessed by the following cardio-respiratory and mechanical variables before and after the training programme: oxygen uptake (VO(2), mL min(-1)), relative oxygen uptake (rel VO(2), mL min(-1).kg(-1)), carbon dioxide (CO(2), mL min(-1)), respiratory quotient (R), heart rate (bpm) and the distance covered in 12 min (the Cooper test, m). Nine patients successfully completed the intervention and measurement protocols without bleeding or other adverse events. After the propo…

Adultmedicine.medical_specialtyHaemophilia AHemophilia AHaemophiliaOxygen ConsumptionHeart RateHemarthrosisHeart ratemedicineHumansLactic AcidExercise physiologyAdverse effectExerciseSwimmingGenetics (clinical)Aerobic capacitybusiness.industryHematologyGeneral Medicinemedicine.diseaseOxygen uptakeExercise TherapyRespiratory quotientMotor SkillsAnesthesiaPhysical EndurancePhysical therapybusinessHaemophilia
researchProduct